BridgeBio
We move at the speed of patient need.
875 employees · est. 2014 · Palo Alto, United States
Homology Medicines
Dedicated to addressing the root cause of rare genetic diseases and promising hope for patients in need.
est. 2015
BridgeBio is the older company (2014 vs 2015).
Side-by-Side Comparison
| Metric | BridgeBio | Homology Medicines |
|---|---|---|
| Founded | ||
| Founded | 2014 older | 2015 |
| Headquarters | ||
| Headquarters | Palo Alto, United States | Not tracked yet |
| Employees | ||
| Employees | 875 | Not tracked yet |
| Industry | ||
| Industry | Biotechnology, Health Care, Life Sciences | Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $3.85B | $187.00M |
| Funding Rounds | ||
| Funding Rounds | 13 | 3 |
| Services | ||
| Services | drug research and development, clinical trials and testing, regulatory submissions, patient support and advocacy, scientific publications and presentations | Not tracked yet |
| Target Customers | ||
| Target Customers | patients with rare genetic conditions, healthcare providers, medical researchers, pharmacists, biotechnology investors | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Genetic MedicineGenetic Disease TherapiesR&D SupportTransformative MedicinesEntrepreneurial ApproachPatient-centric Innovation +8 | Rare Genetic DiseasesGene TherapyNuclease-free Gene EditingAAVHSCsIn Vivo DeliveryHematopoietic Stem Cells +8 |
| Website | ||
| Website | bridgebio.com | homologymedicines.com |
About BridgeBio
BridgeBio, founded in 2014, is a U.S.-based biotech company focused on delivering transformative medicines for genetic conditions, seeking to align genetic and entrepreneurial advances. Their slogan, "We move at the speed of patient need," encapsulates their mission to address urgent patient require...
About Homology Medicines
Homology Medicines, Inc., founded in 2015, is at the forefront of genetic medicine, aiming to transform treatment paradigms for rare genetic diseases. Its distinctive approach utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver gene therapy or perform n...
Also comparing in this category
We will tell you when either one moves
BounceWatch watches BridgeBio and Homology Medicines for new funding, fast hiring, new executives and a change of software vendor. When one happens, it is in your next e-mail.
Get notified when BridgeBio or Homology Medicines moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Frequently Asked Questions
Compare BridgeBio with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at BridgeBio on 11 Mar 2026, and Homology Medicines on 30 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
